Cancer immunotherapies outcomes and burdens validation survey

• Research type

  Research Study

• Full title

  Patient perceptions of outcomes and burdens of receiving immunotherapies for cancer: a validation survey

• IRAS ID

  301424

• Contact name

  Mark Middleton

• Contact email

  mark.middleton@oncology.ox.ac.uk

• Sponsor organisation

  University of Oxford / Research Governance, Ethics, & Assurance

• Duration of Study in the UK

  0 years, 5 months, 31 days

• Research summary

  This is a test survey study to assess the acceptability and properties of a new patient reported outcome measure (PROM) and a questionnaire designed to assess burden of care for patients receiving immunotherapy for an oncological or haematological malignancy.

• REC name

  London - Surrey Research Ethics Committee

• REC reference

  21/PR/1759

• Date of REC Opinion

  31 Jan 2022

• REC opinion

  Further Information Favourable Opinion